OGN Stock Overview
Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.82 |
| 52 Week High | US$23.10 |
| 52 Week Low | US$10.75 |
| Beta | 0.69 |
| 1 Month Change | -30.73% |
| 3 Month Change | -33.13% |
| 1 Year Change | -39.45% |
| 3 Year Change | -67.56% |
| 5 Year Change | n/a |
| Change since IPO | -67.46% |
Recent News & Updates
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Mar 24
Why Organon Is A Top Pick For Income Investors
Mar 18Recent updates
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Mar 24Why Organon Is A Top Pick For Income Investors
Mar 18Organon's (NYSE:OGN) Dividend Will Be $0.28
Feb 17Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Jan 17Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Dec 13Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
Nov 13The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 04Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Sep 19These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way
Sep 13
NEXPLANON And Biosimilars Drive Growth Amid Financial And Market Challenges
Aug 29 NEXPLANON's efficacy and expansion into new international markets are expected to drive significant revenue growth in women's health.Organon & Co.: Cheap With Caveats
Aug 22Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
Aug 09Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price
Aug 07Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Jul 30Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year
May 29Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals
May 10Four Reasons Why Organon Stock Is A Good Buy
May 07Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk
Aug 10Organon & Co.: A Tough Spot To Be In Right Now
Jul 16Shareholder Returns
| OGN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -14.4% | -2.4% | -3.0% |
| 1Y | -39.5% | -8.0% | 4.6% |
Return vs Industry: OGN underperformed the US Pharmaceuticals industry which returned -8% over the past year.
Return vs Market: OGN underperformed the US Market which returned 4.6% over the past year.
Price Volatility
| OGN volatility | |
|---|---|
| OGN Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: OGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OGN's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| OGN fundamental statistics | |
|---|---|
| Market cap | US$2.85b |
| Earnings (TTM) | US$864.00m |
| Revenue (TTM) | US$6.40b |
3.2x
P/E Ratio0.4x
P/S RatioIs OGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OGN income statement (TTM) | |
|---|---|
| Revenue | US$6.40b |
| Cost of Revenue | US$2.69b |
| Gross Profit | US$3.72b |
| Other Expenses | US$2.85b |
| Earnings | US$864.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 01, 2025
| Earnings per share (EPS) | 3.35 |
| Gross Margin | 58.02% |
| Net Profit Margin | 13.49% |
| Debt/Equity Ratio | 1,881.4% |
How did OGN perform over the long term?
See historical performance and comparisonDividends
10.4%
Current Dividend Yield33%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 10:49 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Organon & Co. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Navann Ty Dietschi | BNP Paribas Exane |
| Jason Matthew Gerberry | BofA Global Research |
| Sel Hardy | CFRA Equity Research |